Dre Dominique Trudel, M.D., Ph. D., FRCPC

Pathologist, clinical assistant professor, researcher (CRCHUM)
Pathology and Cellular Biology, University of Montreal
Institut du cancer de Montréal, Montreal University and CRCHUM 


Key words: Prostate Cancer, Ovarian Cancer, Histology, Prognosis, Intraductal Carcinoma of the Prostate, Biomarkers, Immunohistochemistry, immunofluorescence, Raman spectroscopy, Raman microscopy, Imaging Mass Spectrometry.

2004 M.Sc., Université Laval

2005 Medicine, Université Laval

2011 Residency (FRCPC), Anatomic pathology, Université Laval

2013 Clinician-Scientists in Molecular Oncologic Pathology, University Health Network, Toronto, Canada

2014 Ph.D., eperimental medicine, Université Laval

2008-2011 FRQS Doctoral Training for Applicants with a Professional Degree

2015-2019 FRQS Research scholars: Junior 1

  • 2015-2017 (PI) Prostate Cancer Canada, Movember Rising Star Award

    "Intraductal Carcinoma of the Prostate : Imaging Mass Spectrometry for an in Situ Prognostic Oriented Characterization"

  • 2015-2017 (PI) Prostate Cancer Canada, Movember Discovery Grant

    "Adaptation of inelastic scattering detection technology for label-free molecular imaging to improve the reliability of prostatic biopsies"


Awards and prizes 

2014 Junior Scientist Award, Canadian Association of Pathologists

2009 Dr Donald Rix Award, Canadian Association of Pathologists 

2008 Dutkevich Memorial Trust award, Université Laval

2007 Dr Donald W. Penner award, Canadian Association of Pathologists

Prognostic associations of histological and tissue markers in prostate cancer

First axis : Intraductal Carcinoma of the Prostate

Intraductal carcinoma is an aggressive variant of prostate cancer. As the relative survival associated with prostate cancer is over 90% even after 10 years of follow-up, about 30% of men with intraductal carcinoma of the prostate experience recurrence which will eventually lead to death.


Our research is aimed at characterizing this disease histologically and prognostically, as well as in terms of response to treatment.


Second axis : Raman spectroscopy of prostate cancer

For many reasons, the diagnosis of prostate cancer relies on a random sampling of the prostate. As of today, this technique remains the best one to identify men with prostate cancer, but it is associated with approximately 30% of false negatives. Accordingly, the diagnosis of prostate cancer will first be missed in 30% of men who undergo biopsies.


Raman spectroscopy is a laser-based technique relying on the reflection of light on matter to identify its content. Since the reflection of light is specific to the content of tissue, it is possible to perform diagnosis with this technique. In collaboration with Pr Frédéric Leblond’s team, we are developing Raman spectroscopy diagnostic tools specific to prostate cancer.

Associated websites:

  1. CHUM

  2. CRCHUM webpage

  3. PubMed

  4. Research Gate

  5. News - CHUM



  1. Molecular Pathology

  1. Feryel Azzi (Pathologiste de recherche, feryel.azzi.chum@ssss.gouv.qc.ca)

  2. Mirela Birlea (Assistante de recherche, mirela.birlea.chum@ssss.gouv.qc.ca)

  3. Andrée-Anne Grosset (Chercheure postdoctorale, andree-anne.grosset@umontreal.ca)

  4. Mame Kany Diop (PhD., mame.kany.diop@umontreal.ca)

  5. Noémi Roy (MSc., noemy.roy@umontreal.ca)   

  6. Vincent Quoc-Huy Trinh (MSc., quoc-huy.trinh@umontreal.ca)

  1. Trinh, V.Q., et al., The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival. Prostate, 2018. 78(10): p. 697-706.
  2. Aubertin, K., et al., Mesoscopic characterization of prostate cancer using Raman spectroscopy: potential for diagnostics and therapeutics. BJU Int, 2018.
  3. Grosset, A.A., et al., Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis. Appl Immunohistochem Mol Morphol, 2017.
  4. Fraser, M., et al., Genomic hallmarks of localized, non-indolent prostate cancer. Nature, 2017. 541(7637): p. 359-364.
  5. Boutros, P.C., et al., Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet, 2015. 47(7): p. 736-45.
  6. Trudel, D., et al., Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis. Mod Pathol, 2014. 27(10): p. 1394-404.
  7. Trudel, D., et al., Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer, 2014. 50(9): p. 1610-6.
  8. Trudel, D., et al., A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol, 2013. 131(2): p. 357-61.
  9. Trudel, D., et al., 4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. J Histochem Cytochem, 2013. 61(7): p. 500-9.
  10. Trudel, D., et al., Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res, 2003. 63(23): p. 8511-5.